C2N Diagnostics and SouthGenetics Expand Access to Alzheimer’s Blood Testing Across Latin America and the Caribbean
C2N Diagnostics has announced a strategic collaboration with SouthGenetics aimed at expanding access to advanced blood-based testing for Alzheimer’s disease across Latin America and the Caribbean. The partnership is designed to help healthcare professionals in the region gain broader access to C2N’s Precivity® portfolio of blood tests, supporting earlier and more accessible assessment of Alzheimer’s disease in areas facing growing healthcare challenges related to aging populations.
The agreement brings together C2N Diagnostics, a specialty diagnostics company focused on developing innovative tools for neurological diseases, and SouthGenetics, a diagnostics organization with more than two decades of experience introducing molecular and precision medicine technologies throughout Latin America and the Caribbean. Through their combined expertise, the companies hope to improve the availability of diagnostic solutions that can help identify Alzheimer’s disease pathology earlier in the patient journey.
Alzheimer’s disease continues to represent a significant public health challenge worldwide. The burden is particularly increasing in Latin America and the Caribbean, where demographic shifts are leading to larger elderly populations and higher rates of cognitive impairment and dementia. Healthcare systems throughout the region are also facing shortages of dementia specialists and limited access to advanced diagnostic technologies, creating obstacles to timely diagnosis and treatment.
The collaboration seeks to address these challenges by expanding access to C2N’s Precivity® blood tests, which are designed to provide information about amyloid pathology associated with Alzheimer’s disease. Amyloid plaques are considered one of the hallmark biological features of Alzheimer’s disease and play a central role in disease diagnosis and management. By offering a less invasive testing option, the Precivity® portfolio may help healthcare providers gather important clinical information without relying solely on specialized imaging procedures.
According to C2N Diagnostics President and Chief Executive Officer Dr. Joel Braunstein, the company’s Precivity® testing platform was developed to provide healthcare professionals with greater clarity regarding Alzheimer’s disease pathology. He noted that expanding access to blood biomarker testing is increasingly important as healthcare systems prepare for a new era of Alzheimer’s disease treatment and management.
The partnership will initially focus on implementing testing programs in several countries, including Argentina, Chile, Colombia, the Dominican Republic, Ecuador, Jamaica, Mexico, Uruguay, and Venezuela. The companies also plan to evaluate opportunities for expansion into additional markets throughout the region as demand grows and healthcare systems continue to evolve.
Growing interest in Alzheimer’s disease diagnostics is being driven in part by the emergence of disease-modifying therapies. In recent years, regulatory authorities in several countries have approved treatments designed to target the underlying biological mechanisms of Alzheimer’s disease rather than simply managing symptoms. These developments have increased the need for reliable diagnostic tools capable of identifying patients who may benefit from such therapies.
However, many countries in Latin America and the Caribbean face challenges in accessing advanced diagnostic technologies such as amyloid positron emission tomography (PET) imaging. PET scans can help detect amyloid plaques in the brain, but the technology often requires specialized facilities, trained personnel, and significant financial resources. These limitations have made it difficult for many patients to obtain timely evaluations.
Blood-based biomarker tests have emerged as a promising alternative because they can provide important information about Alzheimer’s-related pathology through a simple blood sample. Such tests have the potential to improve accessibility, reduce diagnostic delays, and support clinical decision-making in settings where advanced imaging resources may be limited.
SouthGenetics Chief Executive Officer Washington Rodriguez emphasized that scientific innovation alone is not enough to address healthcare challenges across the region. Successful implementation requires strong logistics networks, physician education programs, and effective country-specific execution strategies. He stated that SouthGenetics was founded to help bridge diagnostic gaps and improve access to advanced testing technologies for patients and healthcare providers.
Under the collaboration, SouthGenetics will leverage its established commercial, medical, and logistics infrastructure to support regional implementation efforts. The company will assist with physician awareness initiatives, facilitate sample collection and transportation, support country-level activation efforts, and help establish pathways that enable appropriate patient access to testing services.
The partnership builds upon C2N’s previous efforts to support Alzheimer’s disease initiatives in international markets. One notable example was the inclusion of the company’s PrecivityAD® test in the Davos Alzheimer’s Collaborative Healthcare System Preparedness Early Detection Flagship Program. This initiative implemented digital cognitive assessments and blood biomarker testing across multiple healthcare sites in several countries, including Mexico and Brazil.
Published findings from the program indicated that the use of blood biomarkers and digital assessment tools improved clinician confidence in diagnosing and managing cognitive impairment. The results suggested that scalable diagnostic approaches could play an important role in primary care and non-specialty settings, particularly in regions where access to dementia specialists remains limited.
Scientific evidence supporting blood-based Alzheimer’s testing continues to grow. Recent research evaluating the PrecivityAD2® blood test has demonstrated promising diagnostic performance. One large clinical study published in JAMA examined a testing approach based on plasma p-tau217 and the Aβ42/Aβ40 ratio in more than 1,200 individuals undergoing cognitive evaluations in primary and secondary care settings.
The study reported high levels of diagnostic accuracy for identifying Alzheimer’s disease pathology. Researchers found that the blood-test approach outperformed traditional clinical evaluations conducted by both primary care physicians and dementia specialists when identifying underlying disease-related changes. These findings have contributed to growing interest in blood biomarkers as practical tools for supporting Alzheimer’s disease assessment.
Additional evidence has been published in npj Dementia, a journal within the Nature Portfolio. Independent validation studies compared the PrecivityAD2® blood test against amyloid PET imaging and reported strong performance measures, including accuracy, sensitivity, and specificity. The findings further reinforced the potential utility of blood-based biomarkers as part of the broader diagnostic process.
C2N Diagnostics has also achieved important regulatory milestones. The company received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its proprietary brain amyloidosis blood test. The designation is intended to support the development and review of technologies that may offer significant advantages over existing diagnostic or treatment options for serious conditions. The company’s test is currently under FDA review.
In addition, the PrecivityAD2® test received medical device registration from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) in 2025, further expanding international recognition of the technology.
Healthcare experts increasingly recognize the importance of early and accurate assessment in Alzheimer’s disease management. Earlier identification of disease pathology can help patients and families better understand their condition, plan for future care needs, and evaluate potential treatment options. It can also assist healthcare providers in making more informed clinical decisions and coordinating appropriate support services.
While blood-based biomarkers represent a significant advancement, C2N emphasizes that Precivity® tests are intended to be used as part of a comprehensive clinical evaluation. The tests provide information that may assist healthcare professionals but are not intended to serve as standalone diagnostic tools for Alzheimer’s disease. Clinical assessments, patient history, cognitive evaluations, and other diagnostic procedures remain important components of the overall evaluation process.
As the prevalence of Alzheimer’s disease continues to rise globally, partnerships such as the one between C2N Diagnostics and SouthGenetics may play an important role in improving access to innovative diagnostic technologies. By combining scientific innovation with regional expertise and healthcare infrastructure, the companies aim to support earlier detection, improved clinical decision-making, and better patient care throughout Latin America and the Caribbean.
The collaboration reflects a broader movement toward more accessible and scalable approaches to Alzheimer’s disease assessment. With growing demand for diagnostic services and increasing interest in disease-modifying therapies, expanding access to reliable blood-based testing could help healthcare systems across the region better prepare for the future of dementia care.
About C2N Diagnostics, LLC
C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation®. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N’s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help healthcare researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 200 Alzheimer’s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer’s disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer’s Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, and Mayo Clinic Laboratories. Over 90,000 Precivity®-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.
